Table of Contents
ISRN Nephrology
Volume 2013, Article ID 184527, 5 pages
Clinical Study

Residual Renal Function in Hemodialysis Patients: The Role of Angiotensin-Converting Enzyme Inhibitor in Its Preservation

1Nephrology Department, Venizeleio Hospital, 71409 Heraklion, Crete, Greece
2Nephrology Department, University Hospital of Heraklion, Voutes, 71100 Heraklion, Crete, Greece
3Department of Biological Sciences, Molecular Medicine Research Center, University of Cyprus, University House “Anastasios G. Leventis,” P.O. Box 20537, 1678 Nicosia, Cyprus

Received 18 October 2012; Accepted 29 November 2012

Academic Editors: C. Escobar, C. Fourtounas, and A. Tzamaloukas

Copyright © 2013 Dimitris Xydakis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis.